<div>Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.</div>